A breakthrough clinical trial has yielded promising results for a new daily weight-loss pill, orforglipron, which has been shown to help people shed pounds and reduce their blood sugar levels.
A significant clinical trial has yielded promising results for a new daily weight-loss pill, orforglipron, which has been shown to help people shed pounds and reduce their blood sugar levels. The trial, conducted by Eli Lilly, the drug’s manufacturer, involved 559 obese individuals with type 2 diabetes from around the world.
The trial found that participants who took a 36mg pill of orforglipron lost an average of 7.3kg (16lbs) over nine months. Additionally, the daily pill reduced blood sugar levels in some cases, bringing them below the formal threshold for diabetes. This is particularly significant, as it suggests that orforglipron may offer a more effective approach to managing type 2 diabetes than existing therapies.
Orforglipron is the first daily pill version of a GLP-1 agonist, a medication used in blockbuster weight-loss injections such as Ozempic and Wegovy. This makes orforglipron an attractive option for those seeking a convenient and effective way to manage their weight and blood sugar levels.
GLP-1 agonists are a class of medications that mimic the action of the hormone GLP-1 (GLP-1).
They play a crucial role in regulating blood sugar levels and promoting weight loss.
These medications work by stimulating insulin release, suppressing glucagon secretion, and slowing gastric emptying.
Studies have shown that GLP-1 agonists can reduce hemoglobin A1c levels by 1-2% and lead to significant weight loss.
They are commonly used to treat type 2 diabetes and are often administered via injection or infusion.
Health officials believe that daily pill versions of the medicine could allow more people to control their weight and blood sugar levels. The results of this trial have been eagerly awaited, and the company has announced plans to apply for approval to market the drug for weight management later this year and for type 2 diabetes next year.
Weight management refers to the process of maintaining a healthy weight through a combination of diet, exercise, and lifestyle changes.
The ideal weight is determined by body mass index (BMI), which calculates an individual's weight in relation to their height.
A BMI between 18.5 and 24.9 is considered normal weight.
Factors influencing weight management include genetics, metabolism, and hormonal imbalances.
Regular physical activity, a balanced diet, and stress management can aid in achieving and maintaining a healthy weight.
Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, noted that ‘these are important results‘ and highlighted the significance of orforglipron‘s ability to lower glucose levels while also meaningfully reducing weight. However, he cautioned that further trials will be necessary to determine the effects of this therapy on cardiovascular outcomes.
The results of the trial will be presented at a meeting of the American Diabetes Association in June before publication in a peer-reviewed journal. With its promising results and potential benefits, orforglipron is poised to become a significant player in the treatment of obesity and type 2 diabetes.
- theguardian.com | New daily weight loss pill shows success at clinical trial
